Alexion Trial Starts Over Ditched Drug Worth 'Billions'
Former shareholders of biopharmaceutical company Syntimmune kicked off a five-day trial in Delaware's Court of Chancery Monday with a former board member who testified the biotech's leading drug candidate could have...To view the full article, register now.
Already a subscriber? Click here to view full article